Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12685162 | 0.89 | NR1H2 (0.39) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL10553045 | 0.85 | NR1H2 (0.39) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL21146832 | 0.85 | GABRG2 (0.43) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL10552835 | 0.84 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL18437161 | 0.83 | NR1H2 (0.37) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL4037148 | 0.83 | CYP2A6 (0.38) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL18848182 | 0.83 | NR1H2 (0.40) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL14291983 | 0.82 | NR1H2 (0.53) | NR1H2NR1H3 | |
| SCHEMBL27108521 | 0.82 | NR1H2 (0.46) | NR1H2GABRG2GABRB3GABRA5NR1H3 | |
| SCHEMBL23092713 | 0.81 | NOD2 (0.44) | NR1H2GABRG2GABRB3GABRA5NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995091-B2 | CXCR4 receptor antagonists | PROXIMAGEN LLC (US) | 2021-05-04 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| US-20170226106-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN, LLC | 2017-08-10 | — | — | US | disclosed |
| WO-2017024003-A1 | 3-(1H-PYRROLO[3,2-C]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2017-02-09 | — | — | WO | disclosed |
| US-9353086-B2 | CXCR4 receptor antagonists | PROXIMAGEN LIMITED (GB) | 2016-05-31 | — | — | US | disclosed |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2016-02-18 | — | — | US | disclosed |
| EP-2627649-B1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2015-04-08 | — | — | EP | disclosed |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | PROXIMAGEN LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
| WO-2005121141-A1 | PYRROLOPYRIDINE DERIVATIVES AND USE THEREOF FOR TREATING DISEASES MEDIATED BY PROSTAGLANDIN D2 (PGD2) | OXAGEN LIMITED (GB) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226106-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | NR1H2 141/4885GABRG2 451/4885GABRB3 465/4885 |
| US-20130289020-A1 | CXCR4 Receptor Antagonists | CXCR4, ACKR3, CXCR1 | NR1H2 175/4885GABRG2 424/4885GABRB3 327/4885 |
| US-20160046606-A1 | CXCR4 Receptor Antagonists | CXCR4, CXCR1, CXCR2 | NR1H2 141/4885GABRG2 451/4885GABRB3 465/4885 |
| US-10995091-B2 | CXCR4 receptor antagonists | CXCR4, CXCR1, CXCR2 | NR1H2 141/4885GABRG2 451/4885GABRB3 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.